Tepotinib Inhibits Several Drug Efflux Transporters and Biotransformation Enzymes: The Role in Drug-Drug Interactions and Targeting Cytostatic Resistance In Vitro and Ex Vivo

Tepotinib is a novel tyrosine kinase inhibitor recently approved for the treatment of non-small cell lung cancer (NSCLC). In this study, we evaluated the tepotinib’s potential to perpetrate pharmacokinetic drug interactions and modulate multidrug resistance (MDR). Accumulation studies showed that te...

Descripción completa

Detalles Bibliográficos
Autores principales: Vagiannis, Dimitrios, Budagaga, Youssif, Morell, Anselm, Zhang, Yu, Novotná, Eva, Skarka, Adam, Kammerer, Sarah, Küpper, Jan-Heiner, Hanke, Ivo, Rozkoš, Tomáš, Hofman, Jakub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584989/
https://www.ncbi.nlm.nih.gov/pubmed/34769363
http://dx.doi.org/10.3390/ijms222111936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8584989/
https://www.ncbi.nlm.nih.gov/pubmed/34769363
http://dx.doi.org/10.3390/ijms222111936

Ejemplares similares